Q-omics provides the consensus-scored LINC01216 profile across patient tissues and cancer cell-line models. LINC01216 expression is associated with patient survival in 11 of 34 cancer types, with the highest sampling consensus in LUSC. Among the 18 cancer types available for tumor–normal comparison, LINC01216 is differentially expressed in 1, with the highest sampling consensus in COAD. Additionally, LINC01216 RNA expression shows 6,075 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight LUSC, COAD, and STAD as cancer lineages where LINC01216 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LINC01216 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LINC01216 survival associations across molecular data types. LINC01216 RNA expression shows survival associations in the most cancer types (11). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LINC01216 RNA expression–survival associations across cancer types. High LINC01216 expression shows unfavorable associations in LUSC, UCS, KIRP, TGCT and PRAD, but favorable associations in ESCA. The LUSC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .006). Together, the overview and detailed table identify LUSC as the clearest survival context for LINC01216 RNA expression.
This table summarizes LINC01216 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 1. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for LINC01216. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LINC01216 shows lower tumor expression in COAD. The COAD box plot shows higher LINC01216 RNA expression in normal versus tumor tissue (log2 FC = −0.008, t-test p = .042).
This table shows molecular features associated with LINC01216 in patient tissues and cancer cell lines. In patient samples, LINC01216 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
